Opthea Limited develops novel therapies for vision-threatening retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Its updates center on sozinibercept, a first-in-class VEGF-C/D trap inhibitor evaluated with standard-of-care anti-VEGF-A therapies for wet AMD, along with clinical publications, conference presentations, and development-program disclosures.
Recurring announcements also cover manufacturing and CMC preparation for sozinibercept, operating and financial results, cash runway commentary, material agreements, shareholder voting matters, capital-structure disclosures, and governance changes for the foreign issuer and its American depositary security program.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.